In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for ...

Enobosarm demonstrated a statistically significant benefit in preserving lean mass in patients with overweight or obesity undergoing treatment with semaglutide.Topline results from the Phase ...

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

Study met primary endpoint: Enobosarm treatment resulted in statistically significant reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002 ... 2024 (GLOBE NEWSWIRE) -- Veru Inc.

It was dubbed the "King Kong" of weight loss drugs by US expert Dr Julio Rosenstock after its effect size emerged , compared to the "gorilla" of Wegovy. The two biggest selling GLP-1 drugs are ...

Versant Ventures continues to invest in the increasingly competitive obesity space, this time launching Helicore with $65 million and a GIP-targeting asset intended to induce higher-quality weight ...

Shares in Veru fell by nearly half following the news, despite positive results in preserving lean muscle mass.

Veru says its mus­cle-main­tain­ing drug pre­served more lean mass in old­er pa­tients tak­ing a GLP-1, but skit­tish in­vestors didn’t cel­e­brate.

Veru said on Monday its experimental drug in combination with Novo Nordisk's weight-loss treatment Wegovy, helped preserve muscle in older patients with obesity, meeting the main goal of a mid-stage ...

Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...